The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.
Laura Quan Man Chow
Research Funding - Bristol-Myers Squibb
Michael S. Gordon
Research Funding - Bristol-Myers Squibb
Theodore F. Logan
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Scott J. Antonia
No relevant relationships to disclose
Shailender Bhatia
Research Funding - Bristol-Myers Squibb
John A. Thompson
Consultant or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Julie R. Brahmer
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Research Funding - Bristol-Myers Squibb
Gretchen Solberg
Employment or Leadership Position - Bristol-Myers Squibb
Rachel Bittner
Employment or Leadership Position - Bristol-Myers Squibb
David Fontana
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Joseph Grosso
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Lewis J. Cohen
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Christoph Matthias Ahlers
Employment or Leadership Position - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Charles G. Drake
Consultant or Advisory Role - Bristol-Myers Squibb